

AMENDMENTS TO THE SPECIFICATION

Please amend the title to read "CXC CHEMOKINE RECEPTOR 4 AGONIST PEPTIDES".

Please replace the paragraphs beginning at page 60, line 5, which starts with "Example 12" with the following amended paragraphs:

Example 12

Table 4-5 shows the effect of the CXCR4 agonist, CTCE-0021, on the mobilization of leukocytes (neutrophils) in mice injected intravenously. CTCE-0021 was injected intravenously into Balb/C mice at 25 mg/kg. To obtain the data in Table 4, blood was collected through cardiac puncture and counted for the increase in white blood cells, and platelets.

Table 3-5. Effect of the SDF-1 agonist, CTCE-0021, on the mobilization of leukocytes (neutrophils) in mice.

Treatment day	Neutrophils ($10^9/l$)	Lymphocytes ($10^9/l$)	Platelets ($10^9/l$)
Day 0 (untreated)	0.968 +/- 0.311	4.78 +/- 0.88	1099 +/- 50
Day 2 (CTCE-0021 treated)	3.159 +/- 0.761	3.15 +/- 1.075	1044 +/- 65
Day 3 (CTCE-0021 treated)	3.209 +/- 0.735	3.371 +/- 1.113	977 +/- 152
Day 5 (CTCE-0021 treated)	1.592 +/- 0.961	5.325 +/- 0.771	882 +/- 88
Day 5 (untreated)	0.893 +/- 0.371	6.540 +/- 0.970	937 +/- 169
Day 8 (CTCE-0021 treated)	2.513 +/- 2.733	4.072 +/- 1.386	1111 +/- 124

In Table 4-5, CTCE-0021 peptide is represented by the following structure: SDF-1 (1-31 K20/E24-cyclic acid) Agonist